Pharmaceutical

LY-3541860 by Eli Lilly and Co for Relapsing Multiple Sclerosis (RMS): Likelihood of Approval

LY-3541860 is under clinical development by Eli Lilly and Co and currently in Phase II for Relapsing Multiple Sclerosis (RMS).

May 17, 2024 - 04:00
LY-3541860 is under clinical development by Eli Lilly and Co and currently in Phase II for Relapsing Multiple Sclerosis (RMS).
Read the original article

Tags:

Previous Article

MRNA-1365 by Moderna for Human Metapneumovirus Infections: Likelihood of Approval

Next Article

LZ-901 by Beijing Luzhu Biotechnology for Herpes Zoster (Shingles): Likelihood o...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

In new order on AI, Biden is scrambling to catch up to emerging risks in health care

In new order on AI, Biden is scrambling to catch up to ...

Oct 30, 2023

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for...

Apr 19, 2024

Seaport raises $225m to advance portfolio of neuropsychiatric prodrugs

Seaport raises $225m to advance portfolio of neuropsych...

Oct 22, 2024